TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...
Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback